Role of surgery in management of type II diabetes

Mount Sinai Journal of Medicine

Volumn 76, Issue 3, 2009, Pages 281-293

  Herron, Daniel M ^a   Tong, Winnie ^a  

^a Department of Surgery   (United States)

Author keywords

Bariatric surgery; Diabetes; Metabolic surgery

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPONECTIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HORMONE; INCRETIN; LEPTIN; PEPTIDE YY;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; CALORIC RESTRICTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; GASTRECTOMY; GASTRIC BANDING; GASTROPLASTY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; LAPAROSCOPIC SLEEVE GASTRECTOMY; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL TECHNIQUE; VERTICAL BANDED GASTROPLASTY; WEIGHT REDUCTION; ANIMAL; METHODOLOGY; TREATMENT OUTCOME;

ANIMALS; BARIATRIC SURGERY; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; TREATMENT OUTCOME;

EID: 67949115772     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20114     Document Type: Review

References (123)

1. Narayan KMV, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden. Diabetes Care 2006; 29: 2114-2116.
2. Abraira C, HendersonWG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-579.
3. Pories WJ, Caro JF, Flickinger EG, et al. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville gastric bypass. Ann Surg 1987; 206: 316-323.
4. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-350.
5. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(suppl 1): S12-S54.
6. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
7. Centers for Disease Control and Prevention. 2007; National Diabetes Fact Sheet. Available at: http://apps.nccd.cdc.gov/ddtstrs/factsheet.aspx. Accessed September 2008.
8. Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294: 1909-1917.
9. Herron DM. The surgical management of severe obesity. Mt Sinai J Med 2004; 71: 63-71.
10. Parikh MS, Fielding GA, Ren CJ. U.S. experience with 749 laparoscopic adjustable gastric bands: intermediate outcomes. Surg Endosc 2005; 19: 1631-1635.
11. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
12. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on T2DM mellitus. Ann Surg 2003; 238: 467-484.
13. Sjostrom L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
14. Sjöström CD, Peltonen M, Wedel H, et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20-25.
15. Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477-484.
16. Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for T2DM mellitus in morbidly obese patients? J Gastrointest Surg 2005; 9: 1112-1116.
17. MacDonald KG Jr, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-220.
18. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003; 237: 751-756.
19. Pories WJ, MacDonald KG Jr, Flickinger EG, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633-642.
20. Long SD, O'Brien K, MacDonald KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994; 17: 372-375.
21. Marceau P, Biron S, Hould FS, et al. Duodenal switch: long-term results. Obes Surg 2007; 17: 1421-1430.
22. Marinari GM, Papadia FS, Briatore L, et al. T2DM and weight loss following biliopancreatic diversion for obesity. Obes Surg 2006; 16: 1440-1444.
23. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005; 10: 2406-2411.
24. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.
25. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with T2DM following bariatric surgery. Diabetes 2003; 52: 1098-1103.
26. Scopinaro N, Papadia F, Camerini G, et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of T2DM by the two operations. Obes Surg 2008; 18: 1035-1038.
27. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25: 358-363.
28. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998; 8: 267-282.
29. Silecchia G, Boru C, Pecchia A, et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg 2006; 16: 1138-1144.
30. Gan SS, Talbot ML, Jorgensen JO. Efficacy of surgery in the management of obesity-related T2DM mellitus. ANZ J Surg 2007; 77: 958-962.
31. Vidal J, Ibarzabal A, Romero F, et al. T2DM mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg 2008; 18: 1077-1082.
32. Balsiger BM, Poggio JL, Mai J, et al. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. Gastrointest Surg 2000; 4: 598-605.
33. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for T2DM: a randomized controlled trial. JAMA 2008; 299: 316-323.
34. Ponce J, Haynes B, Paynter S, et al. Effect of lapband-induced weight loss on T2DM mellitus and hypertension. Obes Surg 2004; 14: 1335-1342.
35. Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 2005; 15: 474-481.
36. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg 1998; 22: 936-946.
37. Hickey MS, Pories WJ, MacDonald KG Jr, et al. A new paradigm for T2DM mellitus: could it be a disease of the foregut? Ann Surg 1998; 227: 637-643.
38. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of T2DM. Ann Surg 2006; 244: 741-749.
39. Lima J, Helena L, Oliveira S, et al. Rapid resolution of diabetes after gastric bypass. Obes Surg 2005; 15: 448-449.
40. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990; 6: 763-770.
41. Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144-1451.
42. Brolin RE, LaMarca LB, Kenler HA, et al. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg 2002; 6: 195-203.
43. Faraj M, Jones P, Sniderman AD, et al. Enhanced dietary fat clearance in postobese women. J Lipid Res 2001; 42: 571-580.
44. MacLean LD, Rhode BM, Nohr CW. Long- or shortlimb gastric bypass? J Gastrointest Surg 2001; 5: 525-530.
45. Sugerman HJ, Londrey GL, Kellum JM, et al. Weight loss with vertical banded gastroplasty and Roux-Y gastric bypass for morbid obesity with selective versus random assignment. Am J Surg 1989; 157: 93-102.
46. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90: 359-365.
47. Kreymann B, Williams G, Ghatei MA, et al. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
48. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-711.
49. Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut 2002; 50: 428-435.
50. Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792.
51. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide- 1 (GLP-1)-(7-36) amide in type 2 (noninsulindependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
52. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322.
53. Mason EE. Ileal [correction of ilial] transposition and enteroglucagon/ GLP-1 in obesity (and diabetic?) surgery. Obes Surg 1999; 9: 223-228.
54. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653-2659.
55. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249-254.
56. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613.
57. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
58. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in T2DM. J Clin Endocrinol Metab 2001; 86: 3853-3860.
59. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
60. Freyse EJ, Becher T, El-Hag O, et al. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes 1997; 46: 824-828.
61. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in T2DM: a parallel-group study. Lancet 2002; 359: 824-830.
62. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981; 5: 471-480.
63. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990; 211: 763-770.
64. Näslund E, Backman L, Holst JJ, et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 1998; 8: 253-260.
65. Valverde I, Puente J, Martín-Duce A, et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005; 15: 387-397.
66. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004; 70: 1-4.
67. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114.
68. Le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780-785.
69. Laferrěre B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with T2DM. Diabetes Care 2007; 30: 1709-1716.
70. Moŕinigo R, Moizé V, Musri M, et al. Glucagonlike peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735-1740.
71. Morínigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 2006; 16: 1594-15601.
72. Bloom SR, Polak JM. Gut hormones. Adv Clin Chem 1980; 21: 177-244.
73. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-1077.
74. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
75. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
76. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994; 51: 63-74.
77. Jorde R, Burhol PG, Johnson JA. The effect of jejunoileal bypass on postprandial release of plasma gastric inhibitory polypeptide (GIP). Scand J Gastroenterol 1981; 16: 313-319.
78. Lauritsen KB, Christensen KC, Stokholm KH. Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass. Scand J Gastroenterol 1980; 15: 489-495.
79. Sirinek KR, O'Dorisio TM, Hill D, et al. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery 1986; 100: 781-787.
80. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of T2DM: a new perspective for an old disease. Ann Surg 2004; 239: 1-11.
81. Rodieux F, Giusti V, D'Alessio DA, et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 2008; 16: 298-305.
82. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
83. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
84. Näslund E, Grybäck P, Hellström PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997; 21: 387-392.
85. Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005; 288: E447-E453.
86. Szecówka J, Tatemoto K, Rajamäki G, et al. Effects of PYY and PP on endocrine pancreas. Acta Physiol Scand 1983; 119: 123-126.
87. Faraj M, Havel PJ, Phélis S, et al. Plasma acylationstimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602.
88. Emilsson V, Liu YL, Cawthorne MA, et al. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997; 46: 313-316.
89. Kieffer TJ, Heller RS, Leech CA, et al. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 1997; 46: 1087-1093
90. Seufert J, Kieffer TJ, Leech CA, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670-676.
91. Lam NT, Cheung AT, Riedel MJ, et al. Leptin reduces glucose transport and cellular ATP levels in INS-1 beta-cells. J Mol Endocrinol 2004; 32: 415-424.
92. Covey SD, Wideman RD, McDonald C, et al. The pancreatic β cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 2006; 4: 291-302.
93. Wauters M, Considine RV, Yudkin JS, et al. Leptin levels in T2DM: associations with measures of insulin resistance and insulin secretion. Horm Metab Res 2003; 35: 92-96.
94. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity 2006; 14: 1553-1561.
95. Infanger D, Baldinger R, Branson R, et al. Effect of significant intermediate-term weight loss on serum leptin levels and body composition in severely obese subjects. Obes Surg 2003; 13: 879-888.
96. Holdstock C, Engström BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177-3183.
97. Molina A, Vendrell J, Gutiérrez C, et al. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003; 13: 615-621.
98. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. 1. Nat Med 2002; 8: 1288-1295.
99. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-154.
100. Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 2005; 15: 692-699.
101. Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002; 10: 1104-1110.
102. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866.
103. Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against T2DM mellitus. Lancet 2003; 361: 226-228.
104. Hanusch-Enserer U, Brabant G, Roden M. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding. N Engl J Med 2003; 348: 2159-2160.
105. Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg 2001; 25: 527-531.
106. Rubino F, Gagner M. Potential of surgery for curing T2DM mellitus. Ann Surg 2002; 236: 554-559.
107. Wang TT, Hu SY, Gao HD, et al. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg 2008; 247: 968-975.
108. Pacheco D, de Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 2007; 194: 221-224.
109. Mason EE. The mechanisms of surgical treatment of T2DM. Obes Surg 2005; 15: 459-461.
110. Patriti A, Facchiano E, Sanna A, et al. The enteroinsular axis and the recovery from T2DM after bariatric surgery. Obes Surg 2004; 14: 840-848.
111. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-2615.
112. Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure T2DM. Ileal transposition improves glucose metabolism and beta-cell function in Goto-Kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery 2007; 142: 74-85.
113. Dolan K, Bryant R, Fielding G. Treating diabetes in the morbidly obese by laparoscopic gastric banding. Obes Surg 2003; 13: 439-443.
114. O'Brien PE, Dixon JB. Lap-band: outcomes and results. J Laparoendosc Adv Surg Tech A 2003; 13: 265-270.
115. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc 2006; 20: 859-863.
116. Vidal J, Ibarzabal A, Nicolau J, et al. Short-term effects of sleeve gastrectomy on T2DM mellitus in severely obese subjects. Obes Surg 2007; 17: 1069-1074.
117. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005; 28: 2406-2411.
118. White S, Brooks E, Jurikova L, et al. Long-term outcomes after gastric bypass. Obes Surg 2005; 15: 155-163.
119. Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002; 87: 3555-3561.
120. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
121. Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents T2DM and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care 2005; 28: 2703-2709.
122. O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006; 144: 625-633.
123. Van Dielen FM, Soeters PB, de Brauw LM, et al. Laparoscopic adjustable gastric banding versus open vertical banded gastroplasty: a prospective randomized trial. Obes Surg 2005; 15: 1292-1298.